GLP-1 RA Drugs: Kidney, Cardiovascular, and Mortality Risks Compared (2025)

Picture this: a wave of excitement sweeping through the medical world over drugs that promise not just better diabetes management, but also weight loss benefits that have everyone talking. These are glucagon-like peptide-1 receptor agonists, or GLP-1 RAs for short, and they've captured public attention like never before, especially with popular options like semaglutide, available under names such as Ozempic and Wegovy. But here's where it gets controversial: while these medications are hailed as game-changers, a new study dives deep into potential risks associated with different versions of them, sparking debates on safety and choice. What if the drug you pick could subtly influence your long-term health in ways we don't fully grasp yet?

Originally developed to help people with type 2 diabetes—a condition where the body struggles to regulate blood sugar effectively (for a refresher, check out this link: https://www.news-medical.net/health/What-is-Type-2-Diabetes.aspx)—GLP-1 RAs work by mimicking a natural hormone that boosts insulin release and curbs appetite. Though they're all lumped under the GLP-1 RA umbrella, tiny differences in their molecular makeup raised eyebrows among experts. That's what led clinical pharmacist and researcher Catherine "Katie" Derington, PharmD, MS, an assistant professor in cardiology at the University of Colorado Anschutz Department of Medicine, to launch an investigation. She wanted to know: do these subtle variations translate into real differences in risks to the kidneys, heart, or even overall survival?

The result? A comprehensive study featured in the prestigious medical journal JAMA Network Open, which analyzed health records from 21,790 veterans living with type 2 diabetes. The team compared three specific GLP-1 RAs—liraglutide, semaglutide, and dulaglutide—looking closely at their impacts on kidney function, cardiovascular health, and mortality rates. And this is the part most people miss: the findings offer reassurance, but they also highlight nuances that could influence treatment decisions in a big way.

Ultimately, Derington and her colleagues discovered that all three drugs carry relatively low risks—a truly hopeful outcome, especially as affordable generic versions of liraglutide hit the market and are poised to become more accessible. Still, she emphasizes that more studies are essential to back up these results. "Our research indicates these medications are quite alike in effectiveness and safety," explains Derington, who also serves as a faculty member at the Adult and Child Center for Outcomes Research and Delivery Science. "This brings peace of mind to patients and confidence to doctors like me when prescribing them."

Why was this study so crucial? Let's break it down for those new to the topic. In the United States, over 38 million people grapple with diabetes, and roughly 90% to 95% of cases are type 2, according to the U.S. Centers for Disease Control and Prevention. Long-term, this condition heightens the chances of heart issues and kidney problems, with heart disease standing out as a top killer among those affected. To tackle this holistically, doctors have embraced the concept of cardiovascular-kidney-metabolic (CKM) syndrome, which spotlights how diabetes, heart conditions, and kidney disease interconnect and compound each other. Think of it like a tangled web where treating one part can ease the others—perhaps lowering blood pressure through diet and exercise, for example, might also protect the kidneys and reduce cardiovascular strain.

"By approaching patients through the lens of CKM syndrome, we treat the whole person and study treatments in a broader context, seeing how they might enhance or protect overall well-being," Derington notes. Over time, GLP-1 RAs have proven to be more than just sugar-lowering tools; they've shown perks like bolstering heart health and safeguarding kidneys. "These are superstar medications," she says, "and we're still unraveling how they deliver these benefits, particularly for kidney function."

Regulators like the U.S. Food and Drug Administration (FDA) have greenlit liraglutide, semaglutide, and dulaglutide to ward off heart-related complications in diabetic patients. Yet, for kidney protection, only semaglutide has FDA approval to slow the progression of chronic kidney disease in those with both diabetes and kidney issues. "To the best of our knowledge, no direct head-to-head trial has pitted these drugs against each other for safety in heart and kidney outcomes," Derington adds. "We aimed to bridge that gap. With their widespread use, high costs, and access challenges, understanding their comparative safety and efficacy is vital—empowering patients and doctors to make informed choices."

Now, onto the data: Derington praises the Department of Veterans Affairs health system as a goldmine of patient information, perfect for a comparative effectiveness study. After a deep dive into the records for liraglutide, semaglutide, and dulaglutide, the researchers found minimal discrepancies in risks to kidneys and cardiovascular health. "They stack up remarkably similarly, meaning patients can choose any with confidence in their safety—a comforting thought," she shares. But here's where it gets controversial again: the data revealed a couple of intriguing differences that challenge assumptions.

For instance, liraglutide showed a slightly lower risk of all-cause mortality—that is, deaths from any cause—compared to dulaglutide. "This caught us off guard," Derington admits, "because we expected them to impact the body in nearly identical ways, given their shared role in preventing heart disease. Is this a genuine effect, or is something else at play? More studies are needed to confirm and explore." On the flip side, semaglutide was linked to a higher chance of gallstones, though the exact "why" remains unclear and these events were exceedingly rare, reinforcing the drugs' overall safety. "It's not cause for panic," she reassures. "For anyone considering these options, I always suggest chatting with your healthcare provider about factors like price, insurance coverage, and ease of use to find the best fit."